AEON Biopharma Balans Gezondheid
Financiële gezondheid criteriumcontroles 2/6
AEON Biopharma has a total shareholder equity of $-27.9M and total debt of $13.3M, which brings its debt-to-equity ratio to -47.6%. Its total assets and total liabilities are $5.7M and $33.7M respectively.
Belangrijke informatie
-47.6%
Verhouding schuld/eigen vermogen
US$13.29m
Schuld
| Rente dekkingsratio | n/a |
| Contant | US$3.44m |
| Aandelen | -US$27.95m |
| Totaal verplichtingen | US$33.68m |
| Totaal activa | US$5.73m |
Recente financiële gezondheidsupdates
Geen updates
Recent updates
Analyse van de financiële positie
Kortlopende schulden: AEON has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Langlopende schulden: AEON has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: AEON has negative shareholder equity, which is a more serious situation than a high debt level.
Schuld verminderen: AEON's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: AEON has sufficient cash runway for 1 months based on last reported free cash flow, but has since raised additional capital.
Voorspelling contante baan: AEON is forecast to have sufficient cash runway for 1 months based on free cash flow estimates, but has since raised additional capital.